Emergingby GlyphFirst patient dosed with partial reprogramming therapy ER-100
Life Biosciences dosed the first participant in its Phase 1 trial of the OSK-based therapy.
Longevity biotechlifebiosciences.com
Life Biosciences
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechDevelops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies. | Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies. | lifebiosciences.com |
Events
FDA clears IND for Life Biosciences' reprogramming therapy ER-100
The clearance lets a Phase 1 trial test ER-100 in glaucoma and NAION patients.
Longevity biotechlifebiosciences.com
Funding
$80M
About
- Source
- lifebiosciences.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- Life Biosciences on Companies
Life Biosciences
Joined in Longevity biotech. Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies.
Life Biosciences
Added in Longevity biotech. Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies.